Liquid Biopsy Market size is expected to reach over USD 26.2 billion by 2030 from at USD 7.1 billion in 2020, expanding growth at a CAGR of 14% from 2021 to 2030.
Get the sample pages of report@ https://www.precedenceresearch.com/sample/1398
What are the Growth Factors?
The global liquid biopsy market growth is driven by rapidly growing number of deaths linked to cancer and rising burden of various types of cancer such as neck and head cancer, colorectal cancer, lungs cancer, breast cancer, and bowel cancer. According to the International Agency for Research on Cancer, the around 19.3 million new cancer cases were observed in 2020 and is expected to grow by 47% to reach 28.4 million new cases by 2040. Therefore, the rising demand for the diagnosis of cancer is driving the demand for the liquid biopsy across the globe.
The liquid biopsy offer certain advantages over the traditional diagnosis techniques like low cost, accuracy, rapid results, and early detection, which makes the liquid biopsy a popular technique among the patients. Moreover, the technological advancements and rising number of developmental strategies being adopted by the market players is influencing the market growth. For instance, the Quest Diagnostics and the Biocept, Inc. collaborated to develop an advanced NGS for the lungs cancer patient in June 2021.
Report Highlights
- Based on the technology, the PCR is expected to be the fastest-growing segment during the forecast period. This is due to the rising adoption of the PCR technique in the diagnosis of cancer owing to its low cost benefit, rapid results, and increased efficacy and accuracy. Moreover, the applications of the PCR is growing in detection of various fungal diseases, bacterial diseases, and other genomic applications, which is expected to drive the growth of the PCR segment.
- Based on the application, the cancer segment dominated the market owing to the increased prevalence of numerous types of cancer among the population and the increasing adoption of the liquid biopsy in the diagnosis. The growing burden of cancer and the increased need for its early detection has fueled the growth of this segment.
- Based on the circulating biomarker, the circulating tumor DNA is estimated to be the most opportunistic segment during the forecast period. This is attributable to the enhanced efficiency of the circulating tumor DNA to detect the cancer early and also detect its mutations. Moreover, this biomarker is extremely efficient for the detection of the breast cancer and the increasing prevalence of breast cancer is fostering the growth.According to the International Agency for Research on Cancer, breast cancer has surpassed the lungs cancer as the most diagnosed type of cancer across the globe in 2020.
- North America dominated the global liquid biopsy market in 2020. This is simply attributed to the increased healthcare expenditure and increased awareness regarding different types of cancer and advanced diagnostic technologies among the population.
- Asia Pacific is expected to be the most opportunistic market in the foreseeable future. The rising government investments in the development of advanced hospitals and rising penetration of numerous diagnostic laboratories in the region is fueling the market growth.
Ask here for customization study@ https://www.precedenceresearch.com/customization/1398
OBJECTIVES OF THE STUDY
- To analyze and forecast the Liquid Biopsy market, in terms of value and volume
- To provide information about the key factors influencing the growth of the market (drivers, restraints, opportunities, and challenges)
- To define, segment, and project the size of the global Liquid Biopsy market on the product type, end-use and other segments
- To project the size of the market, with respect to five main regions, namely, North America, Europe, Asia Pacific (APAC), the Middle East & Africa, and South America, with their key countries
- To strategically analyze micromarkets with respect to individual growth trends, growth prospects, and their contribution to the total market
- To analyze opportunities in the market for stakeholders and provide a competitive landscape of the market leaders
- To strategically profile key players and comprehensively analyze their core competencies
- To track and analyze research & development (R&D) and competitive developments such as joint ventures, mergers & acquisitions, and new product developments in the Liquid Biopsy market
Research Methodology
- Market estimate for 2021
- Average selling price (ASP) per region for specific product type
- Filtrations and assortment of gathered data, to estimate the base year (2021) market size for the country
- Gathering data from company websites, annual reports, white papers, financial reports, broker reports, investor presentations, and SEC filings
- National government documents, statistical databases
- News articles, press releases, and webcasts specific to companies operating in the market
- Country wise analysis through internal and external proprietary databases, and relevant patent and regulatory databases
- Determination of market penetration by country
Major Players Covered in this Report
The updated market research report on Liquid Biopsy market allows the buyers and manufacturers to stay updated with the current market trends, ongoing happenings, and a clear picture on the market scenario. List of key players included in the research report will help the market vendors to know their market position and plan more operational strategies to gain topmost position among other players. The report offers crucial company information on each market player, such as company profile, financial information, and recently adopted growth strategies. This will help other existing players and the new entrants to plan strategies and establish their presence in the market.
Major manufacturers & their revenues, percentage splits, market shares, growth rates and breakdowns of the product markets are determined through secondary sources and verified through the primary sources.
- Company Overview
- Company Market Share/Positioning Analysis
- Product Offerings
- Financial Performance
- Recent Initiatives
- Key Strategies Adopted by Players
- Vendor Landscape
- List of Suppliers
- List of Buyers
Segments Covered in the Report
By Technology
- PCR
- NGS
By Application
- Cancer
- Lungs Cancer
- Breast Cancer
- Colorectal Cancer
- Prostate Cancer
- Others
- Non-Cancer
By Circulating Biomarker
- Circulating Tumor Cells
- Cell-Free DNA
- Circulating Tumor DNA
- Extracellular Vesicles
- Others
By Geography
- North America
- U.S.
- Canada
- Europe
- U.K.
- Germany
- France
- Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of the World
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Liquid Biopsy Market
5.1. COVID-19 Landscape: Liquid Biopsy Industry Impact
5.2. COVID 19 – Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Liquid Biopsy Market, By Technology
8.1. Liquid Biopsy Market, by Technology Type, 2021-2030
8.1.1. PCR
8.1.1.1. Market Revenue and Forecast (2019-2030)
8.1.2. NGS
8.1.2.1. Market Revenue and Forecast (2019-2030)
Chapter 9. Global Liquid Biopsy Market, By Application
9.1. Liquid Biopsy Market, by Application, 2021-2030
9.1.1. Cancer (Lungs Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Others)
9.1.1.1. Market Revenue and Forecast (2019-2030)
9.1.2. Non-Cancer
9.1.2.1. Market Revenue and Forecast (2019-2030)
Chapter 10. Global Liquid Biopsy Market, By Circulating Biomarker
10.1. Liquid Biopsy Market, by Circulating Biomarker, 2021-2030
10.1.1. Circulating Tumor Cells
10.1.1.1. Market Revenue and Forecast (2019-2030)
10.1.2. Cell-Free DNA
10.1.2.1. Market Revenue and Forecast (2019-2030)
10.1.3. Circulating Tumor DNA
10.1.3.1. Market Revenue and Forecast (2019-2030)
10.1.4. Extracellular Vesicles
10.1.4.1. Market Revenue and Forecast (2019-2030)
10.1.5. Others
10.1.5.1. Market Revenue and Forecast (2019-2030)
Chapter 11. Global Liquid Biopsy Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Technology (2019-2030)
11.1.2. Market Revenue and Forecast, by Application (2019-2030)
11.1.3. Market Revenue and Forecast, by Circulating Biomarker (2019-2030)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Technology (2019-2030)
11.1.4.2. Market Revenue and Forecast, by Application (2019-2030)
11.1.4.3. Market Revenue and Forecast, by Circulating Biomarker (2019-2030)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Technology (2019-2030)
11.1.5.2. Market Revenue and Forecast, by Application (2019-2030)
11.1.5.3. Market Revenue and Forecast, by Circulating Biomarker (2019-2030)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Technology (2019-2030)
11.2.2. Market Revenue and Forecast, by Application (2019-2030)
11.2.3. Market Revenue and Forecast, by Circulating Biomarker (2019-2030)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Technology (2019-2030)
11.2.4.2. Market Revenue and Forecast, by Application (2019-2030)
11.2.4.3. Market Revenue and Forecast, by Circulating Biomarker (2019-2030)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Technology (2019-2030)
11.2.5.2. Market Revenue and Forecast, by Application (2019-2030)
11.2.5.3. Market Revenue and Forecast, by Circulating Biomarker (2019-2030)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Technology (2019-2030)
11.2.6.2. Market Revenue and Forecast, by Application (2019-2030)
11.2.6.3. Market Revenue and Forecast, by Circulating Biomarker (2019-2030)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Technology (2019-2030)
11.2.7.2. Market Revenue and Forecast, by Application (2019-2030)
11.2.7.3. Market Revenue and Forecast, by Circulating Biomarker (2019-2030)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Technology (2019-2030)
11.3.2. Market Revenue and Forecast, by Application (2019-2030)
11.3.3. Market Revenue and Forecast, by Circulating Biomarker (2019-2030)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Technology (2019-2030)
11.3.4.2. Market Revenue and Forecast, by Application (2019-2030)
11.3.4.3. Market Revenue and Forecast, by Circulating Biomarker (2019-2030)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Technology (2019-2030)
11.3.5.2. Market Revenue and Forecast, by Application (2019-2030)
11.3.5.3. Market Revenue and Forecast, by Circulating Biomarker (2019-2030)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Technology (2019-2030)
11.3.6.2. Market Revenue and Forecast, by Application (2019-2030)
11.3.6.3. Market Revenue and Forecast, by Circulating Biomarker (2019-2030)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Technology (2019-2030)
11.3.7.2. Market Revenue and Forecast, by Application (2019-2030)
11.3.7.3. Market Revenue and Forecast, by Circulating Biomarker (2019-2030)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Technology (2019-2030)
11.4.2. Market Revenue and Forecast, by Application (2019-2030)
11.4.3. Market Revenue and Forecast, by Circulating Biomarker (2019-2030)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Technology (2019-2030)
11.4.4.2. Market Revenue and Forecast, by Application (2019-2030)
11.4.4.3. Market Revenue and Forecast, by Circulating Biomarker (2019-2030)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Technology (2019-2030)
11.4.5.2. Market Revenue and Forecast, by Application (2019-2030)
11.4.5.3. Market Revenue and Forecast, by Circulating Biomarker (2019-2030)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Technology (2019-2030)
11.4.6.2. Market Revenue and Forecast, by Application (2019-2030)
11.4.6.3. Market Revenue and Forecast, by Circulating Biomarker (2019-2030)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Technology (2019-2030)
11.4.7.2. Market Revenue and Forecast, by Application (2019-2030)
11.4.7.3. Market Revenue and Forecast, by Circulating Biomarker (2019-2030)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Technology (2019-2030)
11.5.2. Market Revenue and Forecast, by Application (2019-2030)
11.5.3. Market Revenue and Forecast, by Circulating Biomarker (2019-2030)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Technology (2019-2030)
11.5.4.2. Market Revenue and Forecast, by Application (2019-2030)
11.5.4.3. Market Revenue and Forecast, by Circulating Biomarker (2019-2030)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Technology (2019-2030)
11.5.5.2. Market Revenue and Forecast, by Application (2019-2030)
11.5.5.3. Market Revenue and Forecast, by Circulating Biomarker (2019-2030)
Chapter 12. Company Profiles
12.1. Bio-Rad Laboratories
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Biocept Inc.
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Guardant Health
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Illumina, Inc.
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. F. Hoffmann-La Roche Ltd.
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Johnson & Johnson
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Laboratory Corporation of America Holdings
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. MDxHealth SA
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. QIAGEN N.V
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Thermo Fisher Scientific Inc.
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Buy this Research Report study@ https://www.precedenceresearch.com/checkout/1398
You can place an order or ask any questions, please feel free to contact at sales@precedenceresearch.com | +1 9197 992 333
